Festival of Biologics
November 2 - 4, 2020 - CHTerrapinn
riette.dejager@terrapinn.com
Phone:+442070921061
1,800+ Attendees. 700+ 1-2-1 Meetings. 350+ Speakers. 100+ Exhibitors. 3 Co-located events The Festival of Biologics is the meeting place for the life science community to bridge the gap between academia and industry. With three events in one, the Festival encourages conversation across the entire industry so you can inspire change, champion innovation, and address complex challenges that the biologics industry is facing. OUR VISION The Festival of Biologics aims to bring together senior biologics professionals across the value chain to showcase their research, collaborate on challenges, forge new connections and ultimately advance the industry to improve patient health. The Festival of Biologics is the meeting place for the life science community to bridge the gap between academia and industry. WHY NOW? Biologics have completely transformed the way that patients are treated. Biologics don't replace older medicines with newer medicines. They increase the range of options for treatments, giving new opportunities for patients and their clinicians. With three events in one, the Festival encourages conversation across the entire industry so you can inspire change, champion innovation, and address complex challenges that the biologics industry is facing. 2020 CONGRESS TRACKS: - AI and Machine Learning in Oncology and Biomarkers - Antibodies in Immunotherapy - Armed Antibodies - Biosimilar Development, Manufacturing and Analysis - Biosimilars in Healthcare Policy - Checkpoint Inhibitors - Clinical Trials - CMC, Developability and Manufacturability - Commercialization and Market Access - Commercialization of Biosimilars and Sustainability of the Industry - Neoantigens - New Technology in Screening and Analytics for Antibody Proteins - Non-Oncology Immunotherapy - Novel Indications for Therapeutic Antibodies - Oncolytic Viruses - The Clinical Environment and Real-world Evidence - Tumor Microenvironment - Value and affordability of Biosimilars